Sign In Join Free
Home Wires

Executive Series - Bionomics (BNO) CEO & Managing Director, Deborah Rathjen

CommSec

Online Stockbroker

Tom Piotrowski speaks with Bionomics (BNO) CEO & Managing Director, Deborah Rathjen about clinical trial results of its anxiety drug BNC210 and its Phase 2 trial for managing Post Traumatic Stress Disorder (PTSD) To view more Executive Series interviews, visit: (VIEW LINK)

CommSec
CommSec View Profile
Online Stockbroker
Online Stockbroker

CommSec is Australia's leading online broker. CommSec has been committed to providing the best in online trading since 1995. CommSec helps make informed investment decisions with comprehensive market research, free live pricing and powerful...

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.

most popular

Equities

Bell Potter's top stock picks for FY23

Bell Potter, Stockbroker

Macro

RBA drops a neutron bomb on the Aussie housing market and makes a heinous mistake in its monetary policy statement

Christopher Joye, Coolabah Capital

Equities

Buy Hold Sell: 5 stocks to play the commodities squeeze

Buy Hold Sell, Livewire Markets

Equities

The Indian companies dominating emerging market returns

Sara Allen, Livewire Markets
view all